Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Internal Medicine
Convalescent Plasma For Covid-19 Complicated By Ards Due To Trali, K. Y. Wang, P. Shah, M. Pierce
Convalescent Plasma For Covid-19 Complicated By Ards Due To Trali, K. Y. Wang, P. Shah, M. Pierce
Journal Articles
© 2021 BMJ Publishing Group. All rights reserved. Convalescent plasma, which contains antibodies from recovered individuals, has been used as an effective treatment for infectious diseases in the past and is currently being used as a potential treatment option for COVID-19. Multiple studies have reported this treatment to be safe. We report a case of a patient who developed acute respiratory distress syndrome (ARDS) with features suggestive of transfusion-related acute lung injury after being treated with convalescent plasma for COVID-19. We emphasise the need to be aware of the potential risk of transfusion reactions and disease worsening with convalescent plasma …
Rationale And Design For The Study Of Rivaroxaban To Reduce Thrombotic Events, Hospitalization And Death In Outpatients With Covid-19: The Prevent-Hd Study, W. H. Capell, E. S. Barnathan, G. Piazza, A. C. Spyropoulos, J. Hsia, S. Bull, C. Lipardi, C. Sugarmann, E. Suh, M. P. Bonaca, +2 Additional Authors
Rationale And Design For The Study Of Rivaroxaban To Reduce Thrombotic Events, Hospitalization And Death In Outpatients With Covid-19: The Prevent-Hd Study, W. H. Capell, E. S. Barnathan, G. Piazza, A. C. Spyropoulos, J. Hsia, S. Bull, C. Lipardi, C. Sugarmann, E. Suh, M. P. Bonaca, +2 Additional Authors
Journal Articles
© 2021 Elsevier Inc. Background: COVID-19 is associated with both venous and arterial thrombotic complications. While prophylactic anticoagulation is now widely recommended for hospitalized patients with COVID-19, the effectiveness and safety of thromboprophylaxis in outpatients with COVID-19 has not been established. Study Design: PREVENT-HD is a double-blind, placebo-controlled, pragmatic, event-driven phase 3 trial to evaluate the efficacy and safety of rivaroxaban in symptomatic outpatients with laboratory-confirmed COVID-19 at risk for thrombotic events, hospitalization, and death. Several challenges posed by the pandemic have necessitated innovative approaches to clinical trial design, start-up, and conduct. Participants are randomized in a 1:1 ratio, stratified …
Ethnic Differences In Thromboprophylaxis For Covid-19 Patients: Should They Be Considered?, T. Iba, J. M. Connors, A. C. Spyropoulos, H. Wada, J. H. Levy
Ethnic Differences In Thromboprophylaxis For Covid-19 Patients: Should They Be Considered?, T. Iba, J. M. Connors, A. C. Spyropoulos, H. Wada, J. H. Levy
Journal Articles
© 2021, Japanese Society of Hematology. Thromboembolic events contribute to morbidity and mortality in coronavirus disease 2019 (COVID-19). As a result, thromboprophylaxis using low-molecular-weight heparin (LMWH) is universally recommended for hospitalized patients based on multiple guidelines. However, ethnic differences with respect to thrombogenicity have been reported and the incidence of thromboembolic events is considered to be lower in the Asian population. Despite the importance of thromboprophylaxis, bleeding is also a side effect that should be considered. We examine the data relating to potential ethnic differences in thrombosis and bleeding in COVID-19. Although sufficient data is not yet available, current evidence …